Antiphospholipid syndrome
Author:
Open Access
- 6 December 2013
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2013 (1) , 675-680
Abstract
The antiphospholipid syndrome (APS) is defined by venous or arterial thrombosis and/or pregnancy morbidity in patients with persistent presence of antiphospholipid antibodies (aPLs). Catastrophic APS is the most severe form of APS, which is associated with rapid development of microvascular thrombosis resulting in multiorgan failure in patients with aPLs. Patients with APS and catastrophic APS are recognized to have a high risk of recurrent thrombosis that can occur despite anticoagulant therapy. Although antithrombotic therapy remains the mainstay of treatment, bleeding manifestations can complicate management and contribute to increased morbidity. Patients with persistently elevated aPL levels, particularly those who exhibit positive testing for lupus anticoagulant, anticardiolipin antibodies, and anti-β2GPI antibodies (triple positivity), appear to be at increased risk for thrombosis and pregnancy complications, whereas isolated positivity for aPLs appears to be associated with low risk. Recognizing that patients with APS have different thrombotic risk profiles may assist clinicians in assessing the risks and benefits of anticoagulation. The optimal type, intensity, and duration of anticoagulation in the treatment of APS remain controversial, particularly for arterial thrombosis and recurrent thrombosis. Future studies that delineate thrombotic risk in APS and evaluate current and novel anticoagulants as well as nonanticoagulant therapies are required.Keywords
This publication has 46 references indexed in Scilit:
- Catastrophic antiphospholipid syndrome: Updated diagnostic algorithmsAutoimmunity Reviews, 2010
- Clinical course of high‐risk patients diagnosed with antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- Update of the guidelines for lupus anticoagulant detectionJournal of Thrombosis and Haemostasis, 2009
- Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the “CAPS Registry”Journal of Autoimmunity, 2009
- V Meeting of the European Forum on Antiphospholipid AntibodiesAutoimmunity Reviews, 2006
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelinesLupus, 2003
- Anticardiolipin cofactor(s) and differential diagnosis of autoimmune diseaseThe Lancet, 1990
- Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).Proceedings of the National Academy of Sciences, 1990
- Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactorThe Lancet, 1990